QQQ   311.37 (-0.11%)
AAPL   156.95 (+4.06%)
MSFT   263.18 (-0.54%)
META   193.83 (+2.68%)
GOOGL   107.34 (-0.37%)
AMZN   108.10 (-4.26%)
TSLA   197.74 (+5.03%)
NVDA   216.18 (-0.42%)
NIO   11.74 (-1.84%)
BABA   107.08 (-2.42%)
AMD   87.86 (-0.51%)
T   19.88 (-1.97%)
F   13.49 (-5.80%)
MU   63.56 (+0.62%)
CGC   3.06 (-2.55%)
GE   82.94 (-1.19%)
DIS   112.50 (-0.63%)
AMC   6.68 (+9.87%)
PFE   44.19 (-0.34%)
PYPL   87.71 (+0.86%)
NFLX   377.39 (+2.86%)
QQQ   311.37 (-0.11%)
AAPL   156.95 (+4.06%)
MSFT   263.18 (-0.54%)
META   193.83 (+2.68%)
GOOGL   107.34 (-0.37%)
AMZN   108.10 (-4.26%)
TSLA   197.74 (+5.03%)
NVDA   216.18 (-0.42%)
NIO   11.74 (-1.84%)
BABA   107.08 (-2.42%)
AMD   87.86 (-0.51%)
T   19.88 (-1.97%)
F   13.49 (-5.80%)
MU   63.56 (+0.62%)
CGC   3.06 (-2.55%)
GE   82.94 (-1.19%)
DIS   112.50 (-0.63%)
AMC   6.68 (+9.87%)
PFE   44.19 (-0.34%)
PYPL   87.71 (+0.86%)
NFLX   377.39 (+2.86%)
QQQ   311.37 (-0.11%)
AAPL   156.95 (+4.06%)
MSFT   263.18 (-0.54%)
META   193.83 (+2.68%)
GOOGL   107.34 (-0.37%)
AMZN   108.10 (-4.26%)
TSLA   197.74 (+5.03%)
NVDA   216.18 (-0.42%)
NIO   11.74 (-1.84%)
BABA   107.08 (-2.42%)
AMD   87.86 (-0.51%)
T   19.88 (-1.97%)
F   13.49 (-5.80%)
MU   63.56 (+0.62%)
CGC   3.06 (-2.55%)
GE   82.94 (-1.19%)
DIS   112.50 (-0.63%)
AMC   6.68 (+9.87%)
PFE   44.19 (-0.34%)
PYPL   87.71 (+0.86%)
NFLX   377.39 (+2.86%)
QQQ   311.37 (-0.11%)
AAPL   156.95 (+4.06%)
MSFT   263.18 (-0.54%)
META   193.83 (+2.68%)
GOOGL   107.34 (-0.37%)
AMZN   108.10 (-4.26%)
TSLA   197.74 (+5.03%)
NVDA   216.18 (-0.42%)
NIO   11.74 (-1.84%)
BABA   107.08 (-2.42%)
AMD   87.86 (-0.51%)
T   19.88 (-1.97%)
F   13.49 (-5.80%)
MU   63.56 (+0.62%)
CGC   3.06 (-2.55%)
GE   82.94 (-1.19%)
DIS   112.50 (-0.63%)
AMC   6.68 (+9.87%)
PFE   44.19 (-0.34%)
PYPL   87.71 (+0.86%)
NFLX   377.39 (+2.86%)
NASDAQ:BNGO

Bionano Genomics - BNGO Stock Forecast, Price & News

$1.96
-0.01 (-0.25%)
(As of 02/3/2023 11:47 AM ET)
Add
Compare
Today's Range
$1.87
▼
$1.97
50-Day Range
$1.40
▼
$2.22
52-Week Range
$1.16
▼
$4.35
Volume
2.58 million shs
Average Volume
6.65 million shs
Market Capitalization
$583.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50

Bionano Genomics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
232.5% Upside
$6.50 Price Target
Short Interest
Bearish
17.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.46mentions of Bionano Genomics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.39) to ($0.38) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.57 out of 5 stars

Medical Sector

895th out of 1,029 stocks

Analytical Instruments Industry

25th out of 27 stocks

See Top Rated MarketRank™ Stocks Here
BNGO stock logo

About Bionano Genomics (NASDAQ:BNGO) Stock

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Receive BNGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionano Genomics and its competitors with MarketBeat's FREE daily newsletter.

BNGO Stock News Headlines

January 23, 2023 | marketbeat.com
NVIDIA Outlook Improving: Watchlist Candidate for 2023 (BNGO)
With less than three weeks gone so far this year, we’re once again excited about NVIDIA’s stock, and aren’t the only ones.
February 2, 2023 | finance.yahoo.com
Bionano’s Symposium 2023 Featured Record Numbers of Presentations Demonstrating Applications of OGM Across Cell Bioprocessing and Constitutional Genetic Disease and Cancer Research
February 3, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
February 2, 2023 | nasdaq.com
BlackRock Increases Position in BioNano Genomics (BNGO)
January 30, 2023 | seekingalpha.com
Bionano's Balance Sheet Challenges: History Repeating Itself
January 26, 2023 | finance.yahoo.com
Are Medical Stocks Lagging Bionano Genomics (BNGO) This Year?
January 25, 2023 | americanbankingnews.com
Bionano Genomics, Inc. (NASDAQ:BNGO) Sees Significant Increase in Short Interest
January 24, 2023 | finance.yahoo.com
Bionano Laboratories Expands its Clinical Testing Menu with Launch of its First OGM-Based Laboratory Developed Test (LDT) for Hematological Malignancies
February 3, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 23, 2023 | finance.yahoo.com
Bionano Announces Launch of Next-Generation Versions of its Reagent Kits and Chip Consumable, Along with Updates to its Instrument Control and Bionano Access Software for the Optical Genome Mapping Workflow
January 20, 2023 | finance.yahoo.com
Bionano Genomics Announces the Final Speaker Lineup for Symposium 2023 with 30 OGM Presentations and Live Panel Discussions Across a Wide Range of Genetic Disease and Cancer Research Applications
January 18, 2023 | finance.yahoo.com
Bionano Announces Publication of Interim Readout from Clinical Trial Run by Consortium Analyzing Optical Genome Mapping as Potential Standard of Care for Prenatal Testing
January 12, 2023 | finanznachrichten.de
Bionano Genomics: Bionano to Accelerate Data Processing Solution for Optical Genome Mapping Workflow with NVIDIA
January 12, 2023 | finance.yahoo.com
Bionano to Accelerate Data Processing Solution for Optical Genome Mapping Workflow with NVIDIA
January 11, 2023 | finance.yahoo.com
Bionano Announces Publication from Institut Curie Showing Utility of OGM for Detection of HRD in Breast Cancer
January 10, 2023 | finance.yahoo.com
Bionano Genomics Announces 2023 Symposium: Four Consecutive Days of OGM Presentations and Live Panel Discussions Across a Wide Range of Genetic Disease and Cancer Applications
January 6, 2023 | finance.yahoo.com
Bionano Genomics to Host Strategy Day on February 2, 2023 in New York City
January 5, 2023 | finance.yahoo.com
Bionano Genomics Reports Preliminary Fourth Quarter and Full-Year 2022 Results
December 30, 2022 | finance.yahoo.com
10 Best High-Risk High-Reward Stocks To Buy Now
December 22, 2022 | finance.yahoo.com
This Innovative Growth Stock Could Double or More in 2023
December 9, 2022 | seekingalpha.com
Bionano announces publication that highlights potential of optical genome mapping
December 9, 2022 | finance.yahoo.com
Multi-Center Research Study Illustrates How OGM Can Potentially Result in More Patients Qualifying for Treatments in Leukemia
December 8, 2022 | finance.yahoo.com
Bionano Genomics Announces American Society of Hematology (ASH) Annual Meeting Presentations Featuring OGM Utility Across Blood Cancer Research Applications
December 1, 2022 | finance.yahoo.com
Bears are Losing Control Over Bionano Genomics, Inc. (BNGO), Here's Why It's a 'Buy' Now
November 28, 2022 | finance.yahoo.com
Bionano Genomics to Acquire Purigen Biosystems to Enable Further Simplified and Accelerated DNA Isolation for Optical Genome Mapping (OGM) and Address Difficult Sample Types in New Applications with Isotachophoresis (ITP) on the Ionic Purification System
November 21, 2022 | benzinga.com
CapitalGainsReport Sector Spotlight: Healthcare Penny Stocks On The Move (ARDX, WHSI, BNGO)
November 21, 2022 | finance.yahoo.com
Publication Shows Utility of OGM in Solid Tumor Research with Study on Detection of Complex Genomic Rearrangements in Prostate Cancer
See More Headlines
Receive BNGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionano Genomics and its competitors with MarketBeat's FREE daily newsletter.

BNGO Company Calendar

Last Earnings
8/03/2021
Today
2/03/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BNGO
CUSIP
N/A
CIK
1411690
Web
www.bionanogenomics.com
Phone
(858) 888-7600
Fax
N/A
Employees
299
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.50
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$3.50
Forecasted Upside/Downside
+230.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.41)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-72,430,000.00
Net Margins
-451.42%
Pretax Margin
-473.39%
Return on Equity
-38.48%
Return on Assets
-34.11%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
6.51
Quick Ratio
5.77

Sales & Book Value

Annual Sales
$17.98 million
Price / Sales
32.45
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.17 per share
Price / Book
1.68

Miscellaneous

Outstanding Shares
296,920,000
Free Float
293,361,000
Market Cap
$583.45 million
Optionable
Not Optionable
Beta
2.25

Key Executives

  • Robert Erik Holmlin
    President, CEO, Secretary & Director
  • Mark Oldakowski
    Chief Operating Officer
  • Christopher Stewart
    Chief Financial & Accounting Officer
  • Alka Chaubey
    Chief Medical Officer
  • Jason Priar
    Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BNGO Stock - Frequently Asked Questions

Should I buy or sell Bionano Genomics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bionano Genomics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BNGO shares.
View BNGO analyst ratings or view top-rated stocks.

What is Bionano Genomics' stock price forecast for 2023?

3 analysts have issued twelve-month price objectives for Bionano Genomics' stock. Their BNGO share price forecasts range from $3.50 to $12.00. On average, they anticipate the company's stock price to reach $6.50 in the next year. This suggests a possible upside of 229.9% from the stock's current price.
View analysts price targets for BNGO or view top-rated stocks among Wall Street analysts.

How have BNGO shares performed in 2023?

Bionano Genomics' stock was trading at $1.46 at the beginning of 2023. Since then, BNGO stock has increased by 34.9% and is now trading at $1.97.
View the best growth stocks for 2023 here.

When is Bionano Genomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our BNGO earnings forecast.

How were Bionano Genomics' earnings last quarter?

Bionano Genomics, Inc. (NASDAQ:BNGO) announced its quarterly earnings results on Tuesday, August, 3rd. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.02. The company earned $3.86 million during the quarter, compared to analysts' expectations of $3.30 million. Bionano Genomics had a negative net margin of 451.42% and a negative trailing twelve-month return on equity of 38.48%.

What guidance has Bionano Genomics issued on next quarter's earnings?

Bionano Genomics updated its FY 2022 earnings guidance on Saturday, January, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $27.70 million-$28.00 million, compared to the consensus revenue estimate of $27.44 million.

What is R. Erik Holmlin's approval rating as Bionano Genomics' CEO?

17 employees have rated Bionano Genomics Chief Executive Officer R. Erik Holmlin on Glassdoor.com. R. Erik Holmlin has an approval rating of 73% among the company's employees. 71.0% of employees surveyed would recommend working at Bionano Genomics to a friend.

What other stocks do shareholders of Bionano Genomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bionano Genomics investors own include Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI), Zosano Pharma (ZSAN), ADMA Biologics (ADMA), CNBX Pharmaceuticals (CNBX), KushCo (KSHB), Aeterna Zentaris (AEZS) and Organigram (OGI).

When did Bionano Genomics IPO?

(BNGO) raised $16 million in an IPO on the week of August 20th 2018. The company issued 2,500,000 shares at a price of $6.00-$7.00 per share. Roth Capital Partners and Maxim Group served as the underwriters for the IPO and LifeSci Capital was co-manager.

What is Bionano Genomics' stock symbol?

Bionano Genomics trades on the NASDAQ under the ticker symbol "BNGO."

Who are Bionano Genomics' major shareholders?

Bionano Genomics' stock is owned by a number of retail and institutional investors. Top institutional investors include Bank Julius Baer & Co. Ltd Zurich (0.19%), Inspire Advisors LLC (0.12%), Simplex Trading LLC (0.00%), SG Americas Securities LLC (0.04%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%) and Versor Investments LP (0.02%). Insiders that own company stock include R Erik Holmlin and Yvonne Linney.
View institutional ownership trends.

How do I buy shares of Bionano Genomics?

Shares of BNGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bionano Genomics' stock price today?

One share of BNGO stock can currently be purchased for approximately $1.97.

How much money does Bionano Genomics make?

Bionano Genomics (NASDAQ:BNGO) has a market capitalization of $584.93 million and generates $17.98 million in revenue each year. The company earns $-72,430,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis.

How many employees does Bionano Genomics have?

The company employs 299 workers across the globe.

How can I contact Bionano Genomics?

Bionano Genomics' mailing address is 9540 TOWNE CENTRE DRIVE SUITE 100, SAN DIEGO CA, 92121. The official website for the company is www.bionanogenomics.com. The company can be reached via phone at (858) 888-7600 or via email at arr@lifesciadvisors.com.

This page (NASDAQ:BNGO) was last updated on 2/3/2023 by MarketBeat.com Staff